Wall Street Zen Upgrades Biofrontera (NASDAQ:BFRI) to “Hold”

Biofrontera (NASDAQ:BFRI) was upgraded by equities researchers at Wall Street Zen to a “hold” rating in a research note issued on Saturday.

A number of other equities analysts have also issued reports on the company. Weiss Ratings raised Biofrontera from a “sell (e+)” rating to a “sell (d-)” rating in a report on Wednesday. Zacks Research downgraded Biofrontera from a “hold” rating to a “strong sell” rating in a research note on Friday, July 3rd. One analyst has rated the stock with a Buy rating and two have given a Sell rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of “Reduce”.

Biofrontera Stock Down 1.8%

BFRI stock opened at $1.09 on Friday. The company has a market cap of $13.95 million, a price-to-earnings ratio of -1.12 and a beta of 0.81. The company has a fifty day moving average price of $0.97 and a 200 day moving average price of $0.93. The company has a debt-to-equity ratio of 0.78, a current ratio of 1.20 and a quick ratio of 1.09. Biofrontera has a 12 month low of $0.55 and a 12 month high of $1.21.

Biofrontera (NASDAQ:BFRI) last issued its quarterly earnings data on Thursday, May 14th. The company reported ($0.41) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.12) by ($0.29). Biofrontera had a negative return on equity of 515.34% and a negative net margin of 25.66%.The business had revenue of $10.08 million for the quarter, compared to analysts’ expectations of $10.25 million. Sell-side analysts expect that Biofrontera will post -0.3 earnings per share for the current year.

Institutional Trading of Biofrontera

A hedge fund recently raised its stake in Biofrontera stock. Geode Capital Management LLC lifted its position in shares of Biofrontera Inc. (NASDAQ:BFRI) by 54.2% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 65,677 shares of the company’s stock after acquiring an additional 23,074 shares during the quarter. Geode Capital Management LLC owned 0.56% of Biofrontera worth $37,000 at the end of the most recent quarter. Institutional investors and hedge funds own 10.08% of the company’s stock.

About Biofrontera

Biofrontera AG is a specialty biopharmaceutical company focused on the research, development and commercialization of products for dermatological applications. The company’s core expertise lies in photodynamic therapy (PDT), a treatment modality that uses a photosensitizing agent activated by a specific light source to target diseased skin cells while sparing surrounding healthy tissue.

The flagship product in Biofrontera’s portfolio is Ameluz (aminolevulinic acid hydrochloride 10 % gel), which has received marketing approval in the European Union for treatment of actinic keratosis and basal cell carcinoma, and in the United States for actinic keratosis.